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Many peptides and short proteins have been used as drugs since 
the commercial introduction in the 1920s and 30s of insulin, thyroid 
hormone and factor VIII. Despite the fact that peptides have been 
used for a century to diagnose and treat several kinds of diseases 
such as diabetes and hypothyroidism, they are now considered 
the new generation of biologically active tools. Peptides are key 
regulators in cellular and intercellular responses, with an enormous 
potential for the diagnosis and treatment of various pathological 
conditions such as neuropsychiatric disorders.1 
Several lines of evidence indicate that peptides and proteins exert 
multiple biological actions in the brain such as neurotransmission 
and neuromodulation, regulation of the cerebral blood flow, 
regulation of cerebrospinal fluid secretion, modulation of the blood 
brain barrier (BBB) permeability to nutrients and regulation of the 
internal environment of the brain.2 Neurotransmitter and hormone 
peptides are associated to the modulation of behavior, stress, 
anxiety, aggressiveness, thermoregulation, sleep, pain, learning, 
memory, drug abuse, alcohol intake, and anorexia. Peptides have 
become important targets in neuropharmaceutical drug design for 
the diagnosis and treatment of a wide variety of central nervous 
system (CNS) disorders.1
In spite of their clinical potential, native peptides presented limited 
use due to their poor bioavailability and low stability in physiological 
conditions. Peptides that act in the CNS have been significantly 
impeded by the difficulty of delivering them across the blood brain 
barrier. The ability of a peptide to cross the BBB and enter the 
brain depends on several compositional factors, including size, 
flexibility, conformation, biochemical properties and arrangement 
of amino acids. These factors determine the lipophilicity, hydrogen 
bonding potential, and molecular weight of the peptide. With greater 
understanding of the biology of the BBB, peptide and protein drug 
sites of action, and advances in design principles in medicinal 
chemistry used to change physico-chemical and/or biological 
properties of peptides and proteins, it will be possible to design and 
optimize potential peptide drugs with improved potency, selectivity 
and therapeutic efficacy.
The brain as a major control center is an important target for 
many of these neuropharmaceutical drugs and rational drug 
design is now being used to improve brain bioavailability so that 
potential therapeutics can exert their desired pharmacological 
effects. Considerable efforts have been made to design new drugs 
based on peptides, recent developments in technology and science 
have provided the tools and opportunities to expand the range of 
peptide based drugs in an effort to further understand and diagnose 
neuropsychiatric disorders.3 
Two technologies have been used to improve and add diagnostic 
value to CNS peptide development: nanotechnology and molecular 
imaging. Nanotechnology has produced nanoparticles (NPs) 
with important applications in biological sciences. NPs are solid 
colloidal particles, made of polymeric materials ranging in size 
between 1 and 100nm. When metallic NPs are magnetic, they 
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can be manipulated by an external magnetic field gradient. This 
action at a distance, combined with the intrinsic penetrability of 
magnetic fields into human tissue, opens up many applications 
involving the transport and/or immobilization of magnetic NPs, or 
of magnetically tagged biological targets. Thus, NPs can be used to 
deliver a cargo to a targeted region of the body. Nanoparticles have 
been used for a broad array of applications, and the most promising 
one is the transport of drugs across the BBB. Nanoparticles are 
highly advantageous as delivery vehicles: the loading and release 
of cargo can be controlled; specific molecular-targeting factors can 
be attached; a hydrophilic coating can prevent undesired uptake of 
the nanoparticle by the reticulo endothelial system; and the matrix 
nature of the nanoparticle can provide protection against enzymatic 
and/or chemical degradation of the active agent. Some examples of 
peptides which have been transported to the CNS by nanoparticles 
are Z-DEVD-FMK, a specific caspase inhibitor, and NC-1900, a 
vasopressin fragment analogue.
Molecular imaging is used to study physiological, biochemical 
and pharmacological processes with nanomolar sensitivity in vivo. 
The imaging techniques, positron emission tomography (PET) and 
single photon emission computerized tomography (SPECT) employ 
biomarkers labeled with positron- or γ-emitting radioisotopes, 
enabling the localization of the specific molecule in the target tissue. 
PET and SPECT have clinical applications in neurological diseases 
such as Parkinson’s and Alzheimer’s diseases, and several research 
applications in most neuropsychiatric disorders.4 
Binding affinities in low nanomolar range are a prerequisite for 
successful peptide tracers. Some peptide radioligands include those 
used for somatostatin receptor targeting; Bombesin a 99mTc-ligands 
with high affinity for GRP receptor; and Substance P radioligands with 
affinity for the NK1 receptor, overexpressed in human glioblastoma.5
In Alzheimer’s disease (AD) an amyloid imaging brain scan could 
be developed with Aβ1-40/42 peptide radiopharmaceuticals because 
radiolabeled forms of these molecules are promptly deposited at 
preexisting amyloid plaques in tissues sections of autopsy AD 
brain. Several groups in the world are working in these potential 
peptide radiopharmaceuticals that could be used for imaging brain 
amyloid in living subjects with AD. This neuropeptide are likely to 
be made transportable through the BBB, and provide a diagnostic 
test specific for AD and for assessing the effects in brain of drugs 
that inhibit the formation of Aβ amyloid.4 
In summary, the combined use of radiolabeled and nanoparticles 
encapsulated peptides offers tremendous hope in further 
understanding and diagnosing brain disorders by crossing the BBB 
and providing highly sensitive molecular images. However, they 
must be further studied for their potential diagnosis and clinical 
applications. 
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